A pioneering experimental treatment at University College London Hospitals is giving lupus patients a second chance at life, with incredible results leading to remission and an end to medication. Katie Tinkler, one of the first participants in the trial, expressed her joy, stating, "I’ve never been this good" since her lupus diagnosis 30 years ago.
The revolutionary therapy, which works by resetting the immune system, has provided newfound vigor for patients previously beleaguered by this debilitating disease. Tinkler, who once found everyday activities like walking with her children a struggle, now enjoys skiing and a lifestyle free from lupus medications.
Lupus, an autoimmune disorder affecting around 50,000 people in the UK—predominantly women diagnosed in their young adult years—occurs when the immune system mistakenly attacks the body, leading to debilitating symptoms like joint pain, skin rashes, and potential organ damage.
Tinkler was diagnosed at 20 and battled severe complications from lupus for nearly three decades, culminating in aggressive symptoms over the last decade that necessitated multiple hospital stays. "Lupus at its worst was in bed, unable to move, going downhill rapidly, possibly dying… now I’m living," she said, reflecting on her life before the trial.
Since undergoing the experimental treatment a year and a half ago, Tinkler claims she feels as if she's reclaimed her life, stating, "It’s amazing. I’m living like a normal person… I sort of forgot that you could feel this good." This groundbreaking procedure employs a novel CAR-T (chimeric antigen receptor T-cell) strategy, initially utilized in cancer therapies, to specifically target and eliminate rogue B cells that are responsible for the autoimmune response.
The process involves harvesting patients' T cells and genetically modifying them to attack the malfunctioning B cells. Once reintroduced into the patient’s body, these engineered T cells not only eliminate dysfunctional B cells but also facilitate the growth of new, healthy cells, effectively resetting the immune system.
While initial results show that five out of six patients remain in remission, with one experiencing improved but not complete results, the medical team emphasizes that continued monitoring is crucial. Presenting at the EULAR European Congress of Rheumatology, Dr. Maria Leandro, a consultant rheumatologist involved in the study, celebrated the findings as a significant step forward in lupus treatment, remarking, "If we were to have patients in remission for three to five years consistently, that would be a major gain in lupus."
As researchers aim to expand these promising trials, the medical community watches closely, hopeful that this innovative immune reset could be the key to alleviating the challenges faced by thousands suffering from lupus and other autoimmune conditions.
For more information on this remarkable advancement in lupus treatment, visit the BBC News article here.
Source: BBC Health
